ARTÍCULO MUY RECOMENDABLE EN EL QUE SE EXPLICA DE FORMA SENCILLA TODO EL POTENCIAL DEL TARLATAMAB PARA CONVERTIRSE EN EL UNICO TRATAMIENTO ESTÁNDAR PARA SEGUNDA LINEA SMALL CELL LUNG CANCER EXTENSIVE-STAGE .*.- CONSIGUE MAS OVERALL SURVIVAL QUE LURBINECTEDIN
*.- CONSIGUE MÁS PFS QUE LURBINECTEDIN
*.- REDUCE MÁS MORTALIDAD QUE LURBINECTEDIN Y ...
*.- ES MENOS TÓXICO QUE LURBINECTEDIN ... Y
*.- ... PRODUCE MENOS EFECTOS SECUNDARIOS QUE LURBINECTEDIN ...
¡ BLANCO Y EN BOTELLA !!! .
ASCO25. TARLATAMAB ( IMDELLTRA® ) SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS .
Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy.
TARLATAMAB PROLONGED BOTH OVERALL ( OS ) AND PROGRESIÓN-FREE SURVIVAL ( PFS ) IN THE TREATMENT OF SMALL CELL LUNG CANCER EXTENSIVE-STAGE , BACKING IT AS A SECOND-LINE STANDARD OF CARE .
TARLATAMAB HA BATIDO A LURBINECTEDIN EN LA FASE III CONFIRMATORIA .
LO HA BATIDO EN OVERALL SURVIVAL , PFS , MENOS EFECTOS SECUNDARIOS , TRES PACIENTES CON RESPUESTA COMPLETA .
QUE LAS AUTORIDADES SANITARIAS A NIVEL GLOBAL LE OTORGARÁN LA FULL APPROVAL A TARLATAMAB ES PRÁCTICAMENTE SEGURO .
Y POR TANTO TARLATAMAB PASARÁ A SER EL TRATAMIENTO ESTÁNDAR EN SEGUNDA LÍNEA ...
CON TODO LO QUE ELLO TRAE CONSIGO ...
TENIENDO EN CUENTA QUE TARLATAMAB TIENE TAMBIÉN EL STATUS DE ORPHAN DRUG ... STATUS QUE APORTA EXCLUSIVIDAD DE MERCADO EN CASO DE FULL APPROVAL ...
******************
************
******
TARLATAMAB DEEMED “ PREFERABLE ” SECOND-LINE Therapy FOR SMALL CELL LUNG CANCER .
Caleb Rans, PharmD // JUNE 4 , 2025 .
SECOND-LINE TREATMENT WITH TARLATAMAB IMPROVES PROGRESIÓN-FREE SURVIVAL ( PFS ) AND OVERALL SURVIVAL ( OS ) WHEN COMPARED TO CHEMOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER ( SCLC ), ACCORDING TO RESULTS FROM THE PHASE III DeLLphi-304 TRIAL PRESENTED AT THE ASCO ANUAL MEETING 2025 .
The Efficacy And Safety Data From This Trial “ Clearly Support TARLATAMAB As a PREFERABLE THERAPY ” IN THE SECOND-LINE SETTING , SAID STUDY PRESENTER Charles M. Rudin, MD, PhD, OF MEMORIAL SLOAN KETTERING CÁNCER CENTER IN NEW YORK, NEW YORK .
The DeLLphi-304 Trial (NCT05740566) Enrolled 509 Patients With SCLC Who Had Disease Progresión After FIRST-LINE PLATINUM-BASED CHEMOTHERAPY, With or Without a PD-(L)1 inhibitor . Patients could Have Asymptomatic Brain Metastases ( Treated or Untreated ) .
The PATIENTS Were Randomly Assigned to Receive TARLATAMAB (n=254) or CHEMOTHERAPY (n=255). CHEMOTHERAPY Consisted of TOPOTECAN (n=185), LURBINECTEDIN (n=47), or AMRUBICIN (n=23) .
Baseline Characteristics Were Similar Between The Arms .
In Both Arms, Most Patients Had Received Prior Anti-PD-(L)1 Treatment (71%) and Radiotherapy (63%) .
Ninety-five percent of patients in the TARLATAMAB arm and 93% in the CHEMOTHERAPY arm had DLL3 expression .
TARLATAMAB Improved the Objective Response Rate ( ORR ), Duration Of Response, PFS, and OS .The ORR Was 35% in the TARLATAMAB ARM and 20% in The CHEMOTHERAPY ARM .
THERE WERE 3 COMPLETE RESPONSES IN THE TARLATAMAB ARM AND NONE IN THE CHEMOTHERAPY ARM .
The Median Duration of Response Was 6.8 Months And 5.5 Months, Respectively .
The Median OS Was 13.6 Months in The TARLATAMAB ARM and 8.3 Months in The CHEMOTHERAPY ARM ( Hazard Ratio [HR], 0.60; 95% CI, 0.47-0.77; P <.001 ) .
The 6-Month OS Rates Were 76% and 62%, Respectively .
The 12-Month OS Rates Were 53% and 37%, Respectively .
The Median PFS Was 4.2 Months in The TARLATAMAB ARM and 3.7 Months in The CHEMOTHERAPY ARM (HR, 0.71; 95% CI, 0.59-0.86; P =.002) .
The 6-Month PFS Rates Were 31% and 23%, Respectively .
The 12-Month PFS Rates Were 20% and 4%, Respectively .
Treatment-Related ADVERSE EVENTS ( AEs ) Iccurred in 93% of Patients in The TARLATAMAB ARM and 91% of Those in The CHEMOTHERAPY ARM .
Rates of Grade 3 or Higher Treatment-Related AEs Were 27% and 62%, Respectively .
There Was 1 Treatment-Related Death in The TARLATAMAB ARM, and There Were 4 in The CHEMOTHERAPY ARM . ...
.jpeg)
